New drug MN-001 tested for scarred lungs in tiny trial

NCT ID NCT02503657

Completed Disease control Sponsor: MediciNova Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an experimental drug called MN-001 (tipelukast) in 15 people with moderate to severe idiopathic pulmonary fibrosis (IPF), a lung-scarring disease. Participants took either the drug or a placebo twice daily for six months, then everyone could take the drug for another six months. The goal was to see if MN-001 could slow the decline in lung function and check its safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MN-001 (tipelukast)
What this could lead to: If it works, this could point toward a treatment that slows lung function decline in people with IPF.
What could go wrong: This is a very small early-phase trial with only 15 participants, so results may not be reliable or apply to everyone. The drug may not work better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Fibrosis idiopathic pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC PULMONARY FIBROSIS IPF

Contacts and locations

Locations

Penn State University College of Medicine, Milton S. Hershey Medical Center

Hershey, Pennsylvania, 17033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.